✦ LIBER ✦

Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab

✍ Scribed by Hideyuki Ohzawa, Takashi Sakatani, Toshiro Niki, Yoshikazu Yasuda…

Book ID: 120959130
Publisher: Springer Japan
Year: 2012
Tongue: English
Weight: 269 KB
Volume: 21
Category: Article
ISSN: 1340-6868
DOI: 10.1007/s12282-012-0424-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adding hormonal therapy to chemotherapy

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

✍ Naoki Hayashi, Naoki Niikura, Hideko Yamauchi, Seigo Nakamura, Naoto T. Ueno 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 279 KB

Alterations of the genes involved in the

Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

✍ Mamoru Takada, Toru Higuchi, Katsunori Tozuka, Hiroyuki Takei… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 428 KB

Phase II Randomized Study of Trastuzumab

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

✍ Hurvitz, S. A.; Dirix, L.; Kocsis, J.; Bianchi, G. V.; Lu, J.; Vinholes, J.; Gua 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

Pertuzumab Monotherapy After Trastuzumab

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

✍ Cortes, J.; Fumoleau, P.; Bianchi, G. V.; Petrella, T. M.; Gelmon, K.; Pivot, X. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 497 KB

Phase IIa Trial of Trastuzumab Emtansine

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer

✍ Miller, K. D.; Dieras, V.; Harbeck, N.; Andre, F.; Mahtani, R. L.; Gianni, L.; A 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 148 KB

439 Significantly Higher Pathologic Comp

439 Significantly Higher Pathologic Complete Response Rate with Weekly Compared with Three-weekly Paclitaxel and Carboplatin Plus Trastuzumab Neoadjuvant Therapy – Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer

✍ Z.M. Shao; C.M. Chen; Y. Zhou; S. Chen; Y.F. Hou; G.Y. Liu; G.H. Di; J.S. Lu; J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB